| 抗幽门螺杆菌药物的研究进展 |
| |
| 引用本文： | 刘青,王明伟.抗幽门螺杆菌药物的研究进展[J].生命科学,2005,17(3):211-217. |
| |
| 作者姓名： | 刘青 王明伟 |
| |
| 作者单位： | 中国科学院上海生命科学研究院上海药物研究所,国家新药筛选中心,上海,201203 |
| |
| 基金项目： | 国家重大科技专项基金(2002AA2Z343A)，中国科学院知识创新工程重大项目基金(KSCX1-SW-11-2) |
| |
| 摘 要： | 幽门螺杆菌(Helicobacter pylori)是引起胃炎、胃和十二指肠溃疡乃至胃癌的主要致病菌。近年来，随着大量广谱抗生素的广泛应用使得耐药的幽门螺杆菌菌株呈不断上升趋势，开发高效和高选择性的抗幽门螺杆菌药物已经成为全球关注的课题。本文对近五年来文献报道的抗幽门螺杆菌药物和先导化合物分类进行简要综述，为研究开发幽门螺杆菌感染性疾病的治疗新药提供参考。
|
| 关 键 词： | 研究进展 抗幽门螺杆菌药物 |
| 文章编号： | 1004-0374(2005)03-0211-07 |
| 修稿时间： | 2005年4月4日 |
Advances in studies on novel agents against Helicobacter pylori |
| |
| LIU Qing,WANG Ming-Wei.Advances in studies on novel agents against Helicobacter pylori[J].Chinese Bulletin of Life Sciences,2005,17(3):211-217. |
| |
| Authors: | LIU Qing WANG Ming-Wei |
| |
| Abstract: | Helicobacter pylori is a well-recognized cause for gastritis, peptic ulcer and carcinoma of the stomach. With wide use of broad-spectrum antibiotics, drug-resistant strains of Helicobacter pylori have been emerged in a rapid pace. Development of highly efficacious and selective agents against Helicobacter pylori is thus becoming a focal point that attracts global attention. This article reviews a series of new drugs or lead candi- dates with inhibitory effects on Helicobacter pylori reported in the literature during recent five years, with an aim of providing some useful insights to research and development of novel drugs to treat Helicobacter pylori infection. |
| |
| Keywords: | research progress anti-Helicobacter pylori drugs |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
